Since the emergence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012 in the Arabian Peninsula, many questions remain unanswered on modes of transmission and reservoirs of virus. The MERS-CoV causes severe respiratory illness. The epidemic origins are uncertain but probably linked to a zoonosis. The bat or the camel are discussed as reservoirs of the virus. Globally, since September 2012, WHO has been notified of 1,714 laboratory-confirmed cases of infection with MERS-CoV, including at least 618 related deaths (WHO report -- 14 April 2016).

In such outbreak situations, especially with emerging organisms causing severe human diseases, it is important to quickly develop a test for the detection the virus involved.bioMérieux developed a generic kit, RNA internal control r-gene^®^ (bioMerieux), combining an internal control and a core kit to be used in combination with either proprietary or commercial primers and probes. This tool associated with specific primers and probes constitute a ready-to-use duplex premix for the detection of targeted RNA in a sample.

On this principle, bioMérieux developed a real-time PCR assay for the rapid detection of MERS-CoV. A set of primers and probe and a transcript used as positive control (MERS-HCoV primers r-gene^®^ -- RUO \#20-010 and MERS-HCoV probe r-gene^®^ -- RUO \#20-011, MERS-HCoV transcript -- RUO \#68-010, bioMérieux) were designed on the S gene, coding for the spike structural protein.

The internal control, added before the extraction step, allows to check simultaneously extraction efficiency and presence of inhibitors. Extractions were performed on NucliSENS^®^ easyMAG^®^ (bioMérieux) followed by amplification on 7500 Fast Real-Time PCR System Dx (Applied Biosystems^®^).

Results of analytical sensitivity, exclusivity and inclusivity studies are presented below.

Analytical sensitivity was determined on the whole system using *in vitro* transcript spiked in respiratory samples. This study showed a 95% limit of detection at 2.89 log~10~  cp/mL of sample \[IC 95%: 2.65--3.29\] i.e. 780 cp/mL of sample \[IC 95%: 450--1950\].

Exclusivity was confirmed with the major human respiratory viruses including other human coronaviruses. No cross-reaction was observed. The QCMD Panel MERS-CoV 2015 was tested and results are as expected, Core and educational samples were detected. Among the 19 other commercial kits, all but one gave also the correct identification. The bioMerieux\'s solution targeting S gene gave equivalent results than the kits targeting upE or N gene.

The combination of RNA internal control r-gene^®^ ready-to-use premix with the MERS-CoV primers r-gene^®^, MERS-CoV probe r-gene^®^ and MERS-CoV transcript r-gene^®^ (research use Only) is a good candidate solution for the detection of MERS-CoV virus and demonstrate the interest and reliability of the RNA internal control for the rapid development of detection tool, in outbreak situation.
